Initial Approval: October 11, 2017

## **CRITERIA FOR PRIOR AUTHORIZATION**

Triptodur<sup>®</sup> (triptorelin)

PROVIDER GROUP Professional

**LENGTH OF APPROVAL:** 12 months

**MANUAL GUIDELINES** The following drug requires prior authorization:

Triptorelin (Triptodur®)

## **CRITERIA FOR APPROVAL** (must meet all of the following):

- Patient must have a diagnosis of central precocious puberty must be confirmed with both of the following:
  - Hormone Evaluation:
    - After GnRH or leuprolide administration, a LH (luteinizing hormone) level of > 5 U/L, OR
    - Basal (no stimulation test) serum LH > 5 U/L, OR
    - Basal (no stimulation test) LH > 0.3 U/L using ultra-sensitive assays (chemiluminescence immunoassay)
  - o Bone age advanced one year beyond the chronological age
- Patient must be at least 2 years of age AND below age 11 for females and age 12 for males
- Patient must have onset of secondary sexual characteristics before 8 years of age in females and 9 years of age in males
- Dose must not exceed a single intramuscular injection of 22.5 mg once every 24 weeks

Drug Utilization Review Committee Chair	PHARMACY PROGRAM MANAGER
	DIVISION OF HEALTH CARE FINANCE
	Kansas Department of Health and Environment
 Date	